Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst said, and could mean weak earnings for ...

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer and wants the U.S. drug giant to make ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...

Activist investor Starboard Value has acquired a $1 billion stake in Pfizer to push for strategic changes in the U.S.

This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

As of now, Pfizer’s stock has recorded a year-to-date (YTD) performance of +3.73%. In contrast, the S&P 500 has experienced a much more robust gain of +20.57%. This stark difference in performance ...

RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...

Pfizer’s RSV vaccine, Abrysvo, generated $515 million in revenue in 2023. Pharma giant Pfizer said on Tuesday that it plans to seek regulatory approval to expand the allowed use of its RSV vaccine, ...